Page 1

Competitor Analysis:Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors Reportstack Reportstack Contact contactus@reportstack.com


Summary ď ś

The present Competitive Intelligence Report about Her2 Antibodies Trastuzumab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting Her2 for treatment of Her2 positive breast and gastric cancer as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

ď ś

With the approval and launch of next generation Her2 antibodies Perjeta and Kadcyla, Roche has succeeded in boosting its Her2 franchise lead by Herceptin in 2013 to US$ 7.5 bln (+14% vs previous year).

ď ś

The commercial attractiveness of trastuzumab has stimulated many companies to create and develop next generation anti-Her2 monoclonal antibodies (mabs) with improved properties compared with the humanized antibody trastuzumab. These biosuperior antibodies include antibody-drug conjugates, bi- and multispecific antibodies and engineered Her2 antibodies.

Reportstack Contact contactus@reportstack.com


Summary(Contd‌) ď ś The forthcoming patent expiry for Herceptin has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and launched in less regulated markets. ď ś The report includes a compilation of currently active projects in development of Her2 targeting antibodies for treatment of Her2 positive breast and gastric cancer. In addition, the report lists company-specific R&D pipelines of Her2 antibodies.

Reportstack Contact contactus@reportstack.com


Competitor projects information 

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Reportstack Contact contactus@reportstack.com


If you are interested... ď Ź

Contact Debora White Reportstack Market Research Email: debora@reportstack.com Ph: +1-888-789-6604

http://www.reportstack.com

Reportstack Contact contactus@reportstack.com

Her2 antibodies trastuzumab biosimilars and biobetters,biosuperiors  

The present Competitive Intelligence Report about Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors provides a competito...

Read more
Read more
Similar to
Popular now
Just for you